WallStreetZenWallStreetZen

NYSEMKT: VNRX
Volitionrx Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for VNRX

Based on 1 analyst offering 12 month price targets for Volitionrx Ltd

Min Forecast
$4.00+1,546.09%
Avg Forecast
$4.00+1,546.09%
Max Forecast
$4.00+1,546.09%

Should I buy or sell VNRX stock?

Based on 2 analysts offering ratings for Volitionrx Ltd.

Buy
Strong Buy
1 analysts 50%
Buy
0 analysts 0%
Hold
1 analysts 50%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their VNRX stock forecasts and price targets.

VNRX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-06-18
lockedlocked$00.00+00.00%2026-04-20

1 of 1

Forecast return on equity

Is VNRX forecast to generate an efficient return?

Company
-25.97%
Industry
379.03%
Market
167.34%
VNRX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is VNRX forecast to generate an efficient return on assets?

Company
100.63%
Industry
14.73%
VNRX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

VNRX earnings per share forecast

What is VNRX's earnings per share in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
-$2.13
Avg 2 year Forecast
-$1.83
Avg 3 year Forecast
-$1.21

VNRX revenue forecast

What is VNRX's revenue in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
$2.6M+4.51%
Avg 2 year Forecast
$56.6M+2,203.78%
Avg 3 year Forecast
$9.1M+269.11%
VNRX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

VNRX revenue growth forecast

How is VNRX forecast to perform vs Diagnostics & Research companies and vs the US market?

Company
120.69%
Industry
7.75%
Market
14.52%
VNRX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
VNRX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

VNRX vs Diagnostic & Research Stocks

TickerPricePrice TargetUp/downsideConsensus
VNRX$0.24$4.00+1,546.09%Buy
BIAF$6.06N/AN/A
MBAI$3.24$10.00+208.64%Buy
MDXH$0.60$2.17+261.17%Strong Buy
ISPC$1.07N/AN/A
View Top Diagnostic & Research Stocks

Volitionrx Stock Forecast FAQ

Is Volitionrx Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NYSEMKT: VNRX) stock is to Buy VNRX stock.

Out of 2 analysts, 1 (50%) are recommending VNRX as a Strong Buy, 0 (0%) are recommending VNRX as a Buy, 1 (50%) are recommending VNRX as a Hold, 0 (0%) are recommending VNRX as a Sell, and 0 (0%) are recommending VNRX as a Strong Sell.

If you're new to stock investing, here's how to buy Volitionrx stock.

What is VNRX's earnings growth forecast for 2026-2027?

(NYSEMKT: VNRX) Volitionrx's forecast annual earnings growth rate of N/A is not forecast to beat the US Diagnostics & Research industry's average forecast earnings growth rate of 18.54%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.52%.

Volitionrx's earnings in 2026 is -$26,100,111.On average, 8 Wall Street analysts forecast VNRX's earnings for 2026 to be -$29,133,245, with the lowest VNRX earnings forecast at -$35,046,158, and the highest VNRX earnings forecast at -$22,214,372. On average, 4 Wall Street analysts forecast VNRX's earnings for 2027 to be -$24,990,657, with the lowest VNRX earnings forecast at -$34,778,630, and the highest VNRX earnings forecast at -$14,188,535.

In 2027, VNRX is forecast to generate -$16,521,214 in earnings, with the lowest earnings forecast at -$27,020,321 and the highest earnings forecast at -$5,589,423.

What is VNRX's revenue growth forecast for 2026-2027?

(NYSEMKT: VNRX) Volitionrx's forecast annual revenue growth rate of 120.69% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 7.75%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.52%.

Volitionrx's revenue in 2026 is $2,458,044.On average, 7 Wall Street analysts forecast VNRX's revenue for 2026 to be $35,065,267, with the lowest VNRX revenue forecast at $31,106,946, and the highest VNRX revenue forecast at $39,132,784. On average, 6 Wall Street analysts forecast VNRX's revenue for 2027 to be $772,937,317, with the lowest VNRX revenue forecast at $120,701,503, and the highest VNRX revenue forecast at $1,969,879,099.

In 2027, VNRX is forecast to generate $123,840,861 in revenue, with the lowest revenue forecast at $46,817,387 and the highest revenue forecast at $204,822,656.

What is VNRX's forecast return on assets (ROA) for 2026-2029?

(NYSEMKT: VNRX) forecast ROA is 100.63%, which is higher than the forecast US Diagnostics & Research industry average of 14.73%.

What is VNRX's Price Target?

According to 1 Wall Street analyst that have issued a 1 year VNRX price target, the average VNRX price target is $4.00, with the highest VNRX stock price forecast at $4.00 and the lowest VNRX stock price forecast at $4.00.

The Wall Street analyst predicted that Volitionrx's share price could reach $4.00 by Jun 18, 2027. The average Volitionrx stock price prediction forecasts a potential upside of 1,546.09% from the current VNRX share price of $0.24.

What is VNRX's Earnings Per Share (EPS) forecast for 2026-2027?

(NYSEMKT: VNRX) Volitionrx's current Earnings Per Share (EPS) is -$3.82. On average, analysts forecast that VNRX's EPS will be -$2.13 for 2026, with the lowest EPS forecast at -$2.57, and the highest EPS forecast at -$1.63. On average, analysts forecast that VNRX's EPS will be -$1.83 for 2027, with the lowest EPS forecast at -$2.55, and the highest EPS forecast at -$1.04. In 2027, VNRX's EPS is forecast to hit -$1.21 (min: -$1.98, max: -$0.41).

What is VNRX's forecast return on equity (ROE) for 2026-2029?

(NYSEMKT: VNRX) forecast ROE is -25.97%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.